F033 DataDerm 2.0 – a new era of leveraging technology to add value to patients and practices
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
DataDerm registry data can advance improving skin disease diagnosis and treatment, guide clinical practice, and drive clinically relevant research using real-world data. Participants will describe DataDerm’s registry journey and DataDerm 2.0, a new and more powerful registry platform facilitating registry-based performance improvement and research activities for common and rare skin diseases. Speakers, including experts from DataDerm’s new platform vendor partner, PA Consulting, and data analytics partner OM1, will demonstrate how we will utilize the enhanced platform to improve patient care through research and performance improvement. With a range of patients and practices, DataDerm data reflects real-world conditions and treatments, facilitating care patterns in dermatology.
LEARNING OBJECTIVES
Propose novel ways to leverage registry data to advance the science of dermatology.
Understand how registries and be used to reveal treatment patterns, disease responses, and co-morbidities in inflammatory skin disease.
Understand how DataDerm 2.0 can be used to advocate for the specialty, identify gaps in care, and benefit practices of all types.
SCHEDULE
2:00 PM
DataDerm 2.0 - what we know 10 years after the successful launch of DataDerm 1.0
Robert Swerlick, MD, FAAD
2:15 PM
DataDerm History and Future in the Context of Registry Landscape
Jeffrey Jacobs, MD
2:30 PM
Overview and Demonstration of New DataDerm Platform
Nilesh Chandra
2:55 PM
OM1 Partnership Projects
Joseph Zabinski, PhD
3:15 PM
Registry Features Workgroup Summary: Where Are We Going?
Steven Daniel Daveluy, MD, FAAD
SPEAKERS
Nilesh Chandra
Steven Daniel Daveluy, MD, FAAD
Jeffrey Jacobs, MD
Robert Swerlick, MD, FAAD
Joseph Zabinski, PhD
HANDOUTS
SPEAKER DISCLOSURES
Nilesh Chandra
No financial relationships exist with ineligible companies.
Steven Daniel Daveluy, MD, FAAD
AbbVie – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Incyte – Advisory Board(Honoraria); Insmed – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); UCB – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria);
Jeffrey Jacobs, MD
American Academy of Dermatology – Consultant(Fees); SpecialtyCare – Consultant(Fees);
Robert Swerlick, MD, FAAD
No financial relationships exist with ineligible companies.
Joseph Zabinski, PhD
No financial relationships exist with ineligible companies.